Company news
Maze Therapeutics, Inc. (NASDAQ:MAZE) news
Maze Therapeutics, Inc. news releases on 6ix. Latest, Oct 6, 2026: Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Press releases & updates
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
October 6, 2026
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
September 2, 2026
Maze Therapeutics Announces Appointments to Its Board of Directors
August 13, 2026
Maze Therapeutics Announces $150 Million Registered Offering
April 22, 2026
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
March 24, 2026
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
March 24, 2026
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 5, 2025
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
November 5, 2025
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
November 3, 2025
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
October 5, 2025
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
September 10, 2025
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 10, 2025
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
September 1, 2025
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
August 11, 2025
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
July 9, 2025
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
May 28, 2025
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
May 13, 2025
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
May 12, 2025
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
March 30, 2025
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
February 6, 2025